透過您的圖書館登入
IP:13.59.100.42
  • 期刊
  • OpenAccess

Risperidone Dosage for Children and Adolescents with Psychotic Disorders

兒童青少年精神病患者使用Risperidone治療的劑量

摘要


目的:risperidone是一個非典型抗精神病藥物,本研究的目的是觀察了解台灣兒童青少年精神病患者使用此藥物的治療劑量。方法:2001年6月至2002年3月間,在台灣的多所醫院中收案共103位兒童、青少年及年輕成人之精神病病患,個案接受risperidone治療共十二週,並且至少四週維持相同劑量。個案的基本資料及risperidone的最終治療劑量經過記錄並分析。結果:兒童、青少年及年輕成人之精神病病患,以risperidone治療的平均劑量分別為1.52±0.84, 3.01±1.39與3.10±1.65mg。在66位兒童及青少年精神病個案中,risperidone平均劑量為2.99±1.41mg。在本研究之兒童及青少年精神病個案中,其劑量在性別之間無明顯差異,但與年齡有統計意義的正相關。結論:本研究發現risperidone在台灣兒童青少年精神病個案的治療劑量略低於國外的研究報告。

並列摘要


Objectives: The aim of this observational study was to investigate the typical dosage of the atypical antipsychotic, risperidone, for a sample of children and adolescents with psychotic disorders in Taiwan and compare the results to analogous western studies. Methods: From July 2001 to March 2002, 103 pediatric, adolescent and young adult cases of psychotic disorder being treated at multiple medical centers in Taiwan were enrolled in this study. Subjects underwent treatment with risperidone for at least 12 weeks. Only patients who were stable at the time of assessment and had received a constant dose of risperidone for at least 4 weeks were enrolled in the analysis. Results: The mean daily dosage prescribed for children, adolescents and young adults was 1.52±0.84, 3.01±1.39 and 3.10±1.65 mg, respectively. The mean constant daily dosage of risperidone for 66 pediatric and adolescent cases was 2.99±1.41 mg. Among the pediatric and adolescent cases, risperidone dosage was positively correlated with age whereas there was no significant between-gender difference in risperidone dosage. Conclusion: The results of this study indicate that the average risperidone dosage for children and adolescents with psychotic disorders in Taiwan might be slightly lower compared to analogs from Western countries.

參考文獻


Janssen PAJ,Niemegeers CJE,Awouter F,Shellekens KHL,Megesis AAHP,Meert TF(1988).Pharmaeology of risperidone (R 64 766), a new antipsychotic with 5-HT2 and dopainine-D2 antagonist properties.J Pharmacol Exp Ther.244,685-93.
Chouinard G,Jones B,Remington G(1992).A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidot in the treatment of chronic schizophrenic patients.J Clin Psychopharmacol.13,25-4.
Findling RL,Schulz SC,Reed MD,Blumer JL(1998).The antipsychotics: a pediatric perspective.J Child Adolesc Psychopharmacol.45,1205-32.
Ross J,Martin H(1995).Dosing of antipsychotic agents in pediatric populations.J Child and Adolese Psychopharmacol.5,1-4.
Liu CY,Chin NY,Wu CK,Yuan LM,Hsiao MC,Oscar Liao(2003).Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.Int Clin Psychopharmacol.18,49-51.

延伸閱讀